Abstract B023: Harnessing the dual therapeutic approach of CRISPR/CAS9 and CAR-T cell technologies in KRAS mutated solid tumors

Abstract Kirsten Rat Sarcoma Virus mutation and its complications have been a major concern. Limitations to drawing its accurate configuration, its complications; mutates and thermodynamic properties, have limited their effectiveness as a molecular diagnostic tool. To counteract these challenges, over the years a different set of sophisticated Immunotherapeutic approaches have been adopted such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Caspase Protein System (CAS), and Chimeric Antigen Receptor-T cell (CAR-T). Some of them have already managed approval of the Food and Drug Administration. One of the primary goals of CRISPR/CAS technology is to correct mutations within the genetic sequence, thereby potentially repairing defective genes like KRAS. Meanwhile, CAR-T immunotherapies capitalise on genetically modified T cells. In comparison to traditional therapies, immunotherapies can offer greater safety and precision. However, their efficacy is still questionable while treating solid tumours. Here authors have covered the various key targets such as p53, p21, WNT, and RAS, their success stories over the years and have proposed the importance of targets like KRAS oncogene to manage a better output. KRAS is a RAS family oncoprotein responsible for the development of 85% of different cancers. The missense mutations at the various KRAS hotspots can lead to the development of lung and Pancreatic Cancers. Some of the most recently conducted revolutionary studies synthesize CAR-NK, CAR-M, and CRISPR-Cas9/3/10/Novel CAS systems, as well as their prospective molecular combination to target the KRAS. The purpose of this study is to provide a present status of these therapies, limitations, clinical trials, and a proposal to sketch a combinatorial impact via the PRISMA model for 62 different manuscripts (2001-2024). This format aligns and organizes everything in Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, providing a clear and systematic infographic that represents the process, including stages of selection, screening, and documentation. Citation Format: SDanish Kadir. Harnessing the dual therapeutic approach of CRISPR/CAS9 and CAR-T cell technologies in KRAS mutated solid tumors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer; 2025 Feb 1-4; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2025;85(3 Suppl):Abstract nr B023.